September 23rd, 2006
Cytogen Corporation (Nasdaq: CYTO) has recently published a new data related to its QUADRAMET® (samarium Sm-153 lexidronam injection) product, in an article by Vilmarie Rodriguez, M.D. (a Pediatric Oncologist at The Mayo Clinic in Rochester, Minnesota) entitled “Marrow irradiation with high-dose 153 Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia” […]
By Gloria Gamat -- 0 comments
September 22nd, 2006
Once more, the miracle drug Gleevec, takes center stage.
The leukemia drug Gleevec, though hugely successful has some downsides too: heart failure in a few patients as shown in previous studies and now, drug resistance continues to be a problem.
Now, Kimmel Cancer Center at Thomas Jefferson University may have discovered a way to sidestep such […]
By Gloria Gamat -- 0 comments
September 21st, 2006
Already commercially available, a test known as OncoPlan™, measures the amounts of two members of the same protein family (Shc proteins) -one of which appears to act as an oncogene (tyrosine-phosphorylated (PY)-Shc), and the other as a tumor suppressor (p66 Shc) –thereby helping identify patients with breast cancer who will likely benefit from chemotherapy and […]
By Gloria Gamat -- 0 comments
September 20th, 2006
According to a new model developed by scientists from Group Health and seven other health care organizations in the Breast Cancer Surveillance Consortium (BCSC), breast density is almost equally important as a woman’s in determining her risk of developing breast cancer.
The model, based on the largest study of this issue to-date (in terms of population […]
By Gloria Gamat -- 0 comments
September 19th, 2006
According to a study led by Halcyon Skinner, Ph.D., of Northwestern University with colleagues from Harvard University, revealed that consumption of Vitamin D tablets cuts the risk of pancreatic cancer by nearly half.
One of the first known studies to use a large-scale epidemiological survey to examine the relationship between Vitamin D and pancreatic cancer, the results […]
By Gloria Gamat -- 0 comments
September 18th, 2006
A research group headed by James Morre, Ph.D., professor of medicinal chemistry at Purdue University, obtained results supporting that phenoxodiol (an investigational drug) may be effective in the treatment of prostate cancer by specifically targeting a protein on prostate cancer cells known as tNOX 75 alpha.
The Purdue team has identified the protein, tumor-associated NADH oxidase […]
By Gloria Gamat -- 0 comments
September 18th, 2006
The Phase 2b study in metastatic melanoma of Synta Pharmaceuticals Corp. (Nasdaq: SNTA)’s STA-4783, revealed positive data.
The said Phase 2b study was a randomized, controlled trial in patients with Stage IV metastatic melanoma where STA-4783 plus paclitaxel doubled progression-free survival (PFS), as compared to paclitaxel alone.
Steven O’Day, MD, Chief of Research and Director of Melanoma […]
By Gloria Gamat -- 0 comments
September 15th, 2006
Scientists from the Johns Hopkins Kimmel Cancer Center have completed the first draft of the genetic code for breast and colon cancers, identifying close to 200 mutated genes, most of which were not previously recognized as associated with tumor initiation, growth, spread or control.
According to Victor Velculescu, M.D., Ph.D., assistant professor of oncology at the […]
By Gloria Gamat -- 0 comments
September 14th, 2006
U.S. researchers have recently reported that in children with brain tumors called medulloblastomas, a highly targeted treatment that relies on the patient’s own stem cells led to improved outcomes: from 30-40% chance of surviving to five years to 70-80%.
Chemotherapy usually lasts for 12 months. In this new treatment regimen, radiation therapy is tailored to the […]
By Gloria Gamat -- 0 comments
September 13th, 2006
The unusual combination of a diuretic (amiloride), a Parkinson’s disease medication (carbidopa) and a drug ordinarily used to reverse the effect of sedatives (flumazenil), in a Washington University School of Medicine in St. Louis research was surprisingly found to inhibit the growth of aggressive prostate tumors in laboratory mice.
The said study was not just a […]
By Gloria Gamat -- 0 comments
Recent Comments